Drug intelligence / Profile preview

ARN-1032

Development stage: Preclinical
Lead developer: Arrien Pharmaceuticals
Modality: Small Molecules

Overview

**ARN-1032** is a first-in-class small molecule developed by Arrien Pharmaceuticals LLC using their proprietary Fragment-Field Drug Design (FFDD) technology. It acts as a potent inhibitor of protein kinases, demonstrating strong anticancer activity across various cancer cell lines. The compound was identified in early discovery efforts and underwent lead optimization and initial pharmacokinetic studies as of 2011, with potential applications in oncology as part of a broader pipeline targeting cell signaling pathways in cancer and other diseases.

Targets

SIK2 (Salt inducible kinase 2)

Beyond the preview

Go deeper on ARN-1032.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARN-1032.

Explore the full profile